Investment Rating - The report assigns an "Outperform" rating to multiple stocks in the Hong Kong healthcare sector, including Hansoh Pharma, 3SBio, Kelun-Biotech, Innovent Biologics, Akeso, JD Health, WuXi AppTec, and BeiGene [1][4][37]. Core Insights - The rollout of the "dual formulary" system, which includes the National Reimbursement Drug List (NRDL) and the inaugural Commercial Innovation Drug List, is expected to significantly benefit the innovative drug value chain. The NRDL added 114 drugs with an 88% success rate, up from 76% in 2024, while the commercial list includes 19 innovative drugs [7][40]. - The report highlights three key features of the new drug lists: a focus on innovation, addressing the needs of the elderly and children, and reinforcing the distinction between basic and commercial insurance coverage [7][40]. - The report expresses a long-term positive outlook on the innovative drug value chain, driven by state support for novel drugs and the inclusion of high-innovation therapies in the commercial insurance list [7][40]. Summary by Sections Stock Recommendations - The report lists several top picks for January 2026, including Hansoh Pharma, 3SBio, Kelun-Biotech, Innovent Biologics, Akeso, JD Health, WuXi AppTec, and BeiGene, all rated as "Outperform" [1][4][37]. Market Performance - The December 2025 portfolio of Hong Kong "Golden Picks" saw an average decline of 12.4%, underperforming the Hang Seng Healthcare Index, which fell by 9.5% [5][38]. - Notable performers in December included WuXi AppTec, Akeso, and JD Health, which experienced smaller declines compared to the overall portfolio [5][38]. Industry Trends - The healthcare services sector is noted as undervalued, with companies like Hygeia and Jinxin Fertility showing strong performance due to ongoing market buy-backs [8][41]. - The report suggests monitoring the recovery opportunities in the consumer healthcare sector for 2026, particularly in light of low base effects [8][41]. Recent Developments - A series of business development (BD) deals in December 2025 indicates sustained interest from multinational corporations (MNCs) in the biotech and pharmaceutical sectors, with significant upfront payments and milestone agreements [10][43][44]. - The report emphasizes the attractiveness of the biotech sector following recent valuation resets, suggesting potential for pre-earnings catch-up trades [10][42].

Summary of the Conference Call for Yingen Biotech Company Overview - **Company**: Yingen Biotech - **Key Projects**: - Hertu ADC for endometrial cancer and hormone-positive breast cancer - B7H3 ADC for multiple indications including liver cancer, melanoma, head and neck squamous cell carcinoma, cervical cancer, and platinum-resistant ovarian cancer Core Insights and Arguments - **Hertu ADC Project**: - Shows potential in second-line and later treatment for endometrial cancer and hormone-positive breast cancer - Key registration clinical trial results expected in 2026, with a sales team already established for commercialization [2][5] - **B7H3 ADC Project**: - Demonstrates significant efficacy across various indications with high Objective Response Rate (ORR) and Disease Control Rate (DCR) - No specific expression testing required, indicating broad application potential [2][6] - **Future Catalysts**: - Key clinical trial results for Hertu ADC and submission for market approval - Phase III registration clinical trial for B7H3 ADC in prostate cancer planned for 2026 [2][7] - **Safety Profile**: - B7H3 ADC shows significant safety advantages compared to similar drugs from Merck and Hansoh/GSK, with a lower incidence of interstitial pneumonia [2][9] - **DB1,303 (TOP2 ADC)**: - Comparable efficacy to AstraZeneca's drug and superior to Gilead's, but may face challenges in single-agent indications due to competition [2][10] - **HER3 ADC (DB1,310)**: - Shows significant potential in EGFR-mutant non-small cell lung cancer and hormone-positive breast cancer, with a PFS level of 15 months, outperforming other ADCs [2][11] - **PD-1 VEGF Dual Antibody + ADC Combination**: - Considered a key direction for future cancer treatment, showing good safety and efficacy [2][12] Industry Insights - **Chinese Innovative Drug Industry Outlook for 2026**: - Expected to be broad and optimistic due to the trend of Chinese innovative drugs going global, with companies leading in various technical fields [3] - **Investment Timing**: - Current valuation reflects only part of the potential of Hertu ADC and B7H3 ADC, suggesting significant upside potential as key clinical trial results are released [2][8] - **Global Competition for B7H3 ADC**: - Competitive landscape includes Merck and IDXD, with challenges faced by Merck due to safety issues leading to trial pauses [2][9] - **Upcoming ADC Data Releases in 2026**: - Multiple companies, including Yingen, are expected to release data on various ADC drugs, indicating a rich pipeline and potential industry trends [2][12] Additional Important Points - **Collaborations**: - Yingen collaborates with other companies for various ADC projects, which may yield initial data or enter registration clinical stages in the coming years [2][14][17] - **Early Pipeline Progress**: - Early pipeline projects like PDL1 B7H3 ADC show promising results in broad-spectrum efficacy and low toxicity, supporting further development [2][18]

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing up 0.03% at 26,347.24 points and a total trading volume of HKD 283.46 billion [1] - The Hang Seng Tech Index rose by 0.09%, while the Hang Seng China Enterprises Index fell by 0.22% [1] Blue-Chip Stocks Performance - Kuaishou-W (01024) led blue-chip stocks, surging 11.09% to HKD 73.6, contributing 35.65 points to the Hang Seng Index [2] - Other notable performers included Innovent Biologics (01801) up 6.09% and Chow Tai Fook (01929) up 5.13% [2] - Conversely, China National Petroleum (00857) and Wharf Real Estate (01997) saw declines of 3.52% and 3.57%, respectively, negatively impacting the index [2] Sector Highlights Technology Sector - Major tech stocks mostly rose, with Kuaishou increasing by 11% and Alibaba by over 2% [3] - The brain-computer interface concept gained traction following Elon Musk's announcement of large-scale production plans for Neuralink in 2026 [4] Real Estate Sector - The real estate sector showed strong performance, with Greentown China (03900) rising 6.56% and Shimao Group (00813) up 5.76% [4] - An article in "Qiushi" magazine emphasized the importance of stabilizing market expectations in the real estate sector, suggesting proactive measures to shorten adjustment periods [4] Pharmaceutical Sector - Pharmaceutical stocks performed robustly, with Zhaoyan New Drug (06127) up 13.73% and Yimeng Biotech (09606) up 11.81% [5] - The National Medical Products Administration reported a record number of approved innovative drugs in 2025, significantly exceeding previous years [5] Insurance Sector - Insurance stocks collectively rose, with New China Life (01336) increasing by 5.34% and China Life (02628) by 3.4% [6] - The insurance industry reported a 7.6% year-on-year growth in premium income for the first 11 months of 2025 [6] Automotive Sector - Automotive stocks faced declines, with Great Wall Motors (02333) down 6.15% and XPeng Motors (09868) down 4.6% [6] - The 2026 vehicle trade-in subsidy policy will continue, with adjustments to subsidy amounts based on vehicle pricing [7] Oil Sector - Oil stocks were generally weak, with China National Petroleum (00857) down 3.52% [7] - The geopolitical situation in Venezuela may impact oil prices, with potential increases in production posing risks for future pricing [7] Notable Stock Movements - Woan Robotics (06600) reached a new high, closing up 19.57% at HKD 110, with plans to launch a humanoid home robot in January 2026 [8] - Black Sesame Technologies (02533) rose 11.21% after announcing its high-performance smart driving chip received approval for global sales [9]

1. 脑机接口概念爆发。截至收盘，南京熊猫电子股份(00553)涨39.75%，报6.75港元；微创脑科学 (02172)涨19.73%，报13.53港元；脑动极光-B(06681)涨15.74%，报7.87港元；心玮医疗-B(06609)涨 9.62%，报59.85港元。 据报道，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进 行"大规模生产"。开源证券在最新研报中强调，当前脑机接口行业正处于技术突破、政策扶持与机器人 生态协同三大驱动力共振的高增长蓄势阶段。据Precedence Research预测，全球脑机接口市场规模有望 在2034年达到124亿美元，2025至2034年复合年增长率达17%。 2. 内房股表现亮眼。截至收盘，绿城中国(03900)涨6.56%，报8.93港元；世茂集团(00813)涨5.76%，报 0.202港元；华润置地(01109)涨5.05%，报29.12港元；龙湖集团(00960)涨4.81%，报9.16港元。 港股三大指数今早冲高回落，盘中均一度录得下跌，恒指及恒科指数尾盘翻红。截止收盘，恒生指数涨 0.03%或8.77点， ...

Core Viewpoint - The stock of Envision Biotech-B (09606.HK) has increased by over 12%, reaching a price of 332.2 HKD with a trading volume of 321 million HKD [2] Group 1 - Envision Biotech-B's stock price rose by 12.08% [2] - The current trading price is 332.2 HKD [2] - The total trading volume amounted to 3.21 billion HKD [2]

Investment Rating - The report maintains an "Outperform" rating for the following A-share targets: Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, MicroPort EP MedTech [5][36][8] - The report also maintains an "Outperform" rating for the following H-share targets: Hansoh Pharmaceutical Group, 3SBio, PATEO Biotech, Akeso, and related targets: Innovent Biologics, WuXi AppTec [8][36] Core Insights - The report continues to recommend the innovative drug and device industry and its supply chains, indicating a positive outlook for this sector [1][36] - In December 2025, the pharmaceutical sector underperformed the market, with the SW Pharmaceutical and Biological index falling by 4.1%, while the SHCOMP rose by 2.1%, ranking 26th among Shenwan primary industries [15][37] - The report highlights that the premium level of the pharmaceutical sector relative to all A-shares is currently at a normal level, with a relative premium rate of 63.2% as of the end of December 2025 [25][37] Summary by Sections A-Share Targets - The report includes a monthly portfolio of A-share targets that outperformed the pharmaceutical index, with a monthly average decline of 1.8% compared to the overall pharmaceutical index decline of 3.9% in December 2025 [11][36] - The top three stock gains in December 2025 were Luyan Pharma (+118.8%), CareRay Digital Medical Technology Co., Ltd. (+36.6%), and Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (+34.0%) [24][37] H-Share Targets - The report notes that the Hong Kong stock pharmaceutical sector also underperformed the market, with the Hang Seng Healthcare index falling by 9.5% and the Hong Kong Biological Technology index falling by 10.6% in December 2025 [26][38] U.S. Market Performance - In December 2025, the U.S. pharmaceutical sector underperformed the market, with the S&P 500 Healthcare Select Sector declining by 1.5% while the S&P 500 fell by only 0.1% [26][39]

Group 1 - The core viewpoint of the article highlights that Innovent Biologics-B (09606) has seen a significant stock increase of over 12%, currently trading at 332.2 HKD with a transaction volume of 321 million HKD [1] - According to Guotai Junan Securities, Innovent Biologics is expected to have a rich pipeline of catalysts in 2026, with key data points anticipated including final results from global registration clinical trials for HER2ADC targeting EC and BC indications [1] - The firm also expects clinical results for B7H3ADC, HER2ADC, and TROP2ADC in combination with PDL1*VEGF dual antibody BNT327, as well as updates on early clinical data for B7H4ADC and EGFR*HER3ADC, and progress on CDH17ADC [1] Group 2 - The firm has raised the peak global sales expectations for HER2ADC DB1303, B7H3ADC DB1311, and HER3ADC DB1310 based on the smooth progress of Innovent Biologics' pipeline in 2025 [1] - Using the DCF valuation method, the target price for Innovent Biologics has been increased to 455.56 HKD, while maintaining a buy rating [1]

Core Viewpoint - The stock of InnoCare Pharma (09606) has risen over 12%, currently trading at 332.2 HKD with a transaction volume of 321 million HKD, driven by positive expectations regarding its clinical pipeline and potential market performance in 2026 [1] Group 1: Clinical Pipeline Expectations - Cathay Securities highlights that InnoCare Pharma has a rich pipeline of catalysts expected in 2026, including final results from global registration clinical trials for HER2 ADC targeting EC and BC indications [1] - Anticipated clinical results for B7H3 ADC, HER2 ADC, and TROP2 ADC in combination with PDL1*VEGF dual antibody BNT327 are also on the horizon [1] - Updates on early clinical data for B7H4 ADC and EGFR*HER3 ADC, as well as clinical progress for CDH17 ADC, are expected [1] - Initial data disclosure for the early pipeline PDL1*B7H3 ADC is also anticipated [1] Group 2: Sales Forecast and Valuation - Based on the smooth progress of InnoCare's pipeline in 2025, expectations for peak global sales potential for HER2 ADC DB1303, B7H3 ADC DB1311, and HER3 ADC DB1310 have been increased [1] - Using the DCF valuation method, Cathay Securities has raised the target price for InnoCare Pharma to 455.56 HKD while maintaining a buy rating [1]

Group 1 - The core viewpoint of the articles highlights a significant surge in the Chinese innovative drug sector, with license-out transactions exceeding $130 billion, marking a year-on-year increase of over 150% and surpassing 50% of the global total for the first time [1] - The cash flow generated from business development (BD) and the IPO boom is providing ample funding for research and development, which is crucial for the industry's future growth [1] - Three main driving forces for the industry in 2026 are identified: commercialization realization, clinical data validation, and improvement of payment systems, which are expected to usher in a new era of "value realization" [1] Group 2 - The Hang Seng Medical ETF (159892) focuses on innovative drugs, CXO, and related industries, benefiting from the advantages of the Hong Kong Stock Exchange's 18A system, which covers numerous innovative targets [2] - The ETF is expected to continue its valuation recovery trend under the catalysts of innovative drug exports and commercial insurance directories [2]

Core Viewpoint - Cathay Securities has raised the target price for Immune-Oncologics (09606) to HKD 455.56 based on the optimistic progress of its pipeline leading to potential global sales peak for HER2ADC DB1303, B7H3ADC DB1311, and HER3ADC DB1310 [1] Group 1 - The company is expected to have a rich catalyst in 2026, with anticipated data readouts including final results for HER2ADC in EC and BC indications, clinical results for B7H3ADC, HER2ADC, and TROP2ADC combined with PDL1*VEGF dual antibody BNT327, and updates on early clinical data for BD pipeline B7H4ADCEGFR*HER3ADC and CDH17ADC [2] - The company has confidence in the global registration results and NDA for HER2ADC DB1303 in 2026, based on the smooth progress of two registration clinical trials in 2025 and the optimistic attitude from BNTX's latest R&D day [2] - The company anticipates launching the first global registration Phase III clinical trial for B7H3ADC DB1311 targeting 2L CRPC (chemo naïve) in 2026, given its potential for broad-spectrum solid tumors and outstanding efficacy in CRPC [2] Group 2 - The company expects to continue advancing DB1310 in the global clinical development for 2L+HR+/HER2-BC in 2026, based on the initiation of MSD's HER3ADC in the same indication and DB1310's superior clinical performance [3] - The company believes that DB1305's efficacy can be comparable to DATO, based on updates on solid tumors and TNBC data in 2025 [3] - The company is optimistic about the performance of BNTX's PDL1*VEGF dual antibody BNT327 combined with DB1311 and DB1303DB1305, considering the rapid global clinical progress and rich data volume from both BNTX and Immune-Oncologics [3]